

**Perioperative Use Of Vedolizumab In Crohn's Disease Patients And Surgical**

**outcomes**

UNDER PEER REVIEW

## **Abstract**

Despite advancement in managing Crohn's disease (CD), a considerable proportion of cases still need surgical intervention, which is an essential means in therapy algorithms. Other drugs of the biologics are recently available, while most CD cases having operations have previously received a drug of this class. This class of agents has a direct association with higher postoperative complication rates, which raises a lot of controversies. In this review summarize the essential data concerning the vedolizumab effect on CD's postoperative results. The previous data did not demonstrate a cause-effect absolute connection between the increased postoperative morbidities and vedolizumab. Many routing factors unquestionably affect CD's postoperative outcomes and complications, like malnutrition, unsuitable abdominal settings, and steroids' previous use. Using vedolizumab perioperatively seems safe. Nevertheless, a definitive relationship from the available data is controversial. Personalized, multidisciplinary evaluations and decisions should be made for each case independently, adjusting the surgical plan regarding the involved risk factors.

## Introduction

Crohn's disease (CD) is a GI tract disease with idiopathic chronic inflammation. It occurs in the United States to around 800,000 subjects, while its incidence continuously increases without knowing the reason [1]. For Medical treatment, Biologics are known to be the primary choice for moderate to severe cases; however, the limitation by secondary response [2-10] loss and non-response, in addition to opportunistic infection risks, has been found to affect their benefit [11]. Almost 70 – 75% of cases undergo surgical intervention as a part of the treatment course despite receiving several immunosuppressives [12]. Morbidity rates postoperatively are up to 30%, while following-anastomosis intraabdominal sepsis might happen in around 10% [13, 14]. For better understanding the correlation between taking immunosuppressive agents perioperatively and the increased morbidity postoperatively, numerous studies have been made, particularly the morbidity of infectious type. Exacerbation of postoperative complications may be a risk with administering immunosuppressive agents like corticosteroids and biologics as anti-tumor necrosis factor-alpha (anti-TNF $\alpha$ ) [15, 16]. The current evidence is still indecisive, although many systematic reviews and meta-analyses concluded that an increased risk of complications might be seen postoperatively in patients with inflammatory bowel disease (IBD) receiving anti-TNF $\alpha$  preoperatively [13, 17-23].

Biologics have made considerable advancements in the management and treatment of IBD and have turned to be the backbone in managing moderate to severe cases with Crohn's disease [24]. Anti-TNF $\alpha$  agent (adalimumab, infliximab, and pegol), and the recent antibodies hindering  $\alpha 4\beta 7$  integrins (vedolizumab) on leukocytes, and the

interleukins p40 subunit (IL)-12 and 23(ustekinumab) are very effective agents of biologics for CD [25], which can initiate remission with maintaining it, help the mucosa to heal, and diverse the disease of its standard course when using them on the right time evading the progression to fistula formation and stenosis [26]. Despite the therapeutic algorithms' remarkable improvement, a critical number of CD patients still require surgery, but surgery rates have decreased with the biological agents [27, 28].

Vedolizumab is a monoclonal antibody from Entyvio™, Takeda Pharmaceuticals America, and it got approval in May 2014 by the FDA for treating IBD. Due to vedolizumab's gut selectivity, its introduction to the clinical world has raised significant enthusiasm [29-31]. It is essential to comprehend how to postoperatively alleviate the risk due to the considerable number of CD patients having abdominal procedures while taking immunosuppressive agents and the possibility of refractory disease. The data explaining the effect of perioperative vedolizumab using on surgical outcomes remain inconclusive. In this study, we aimed to review the perioperative use of vedolizumab in patients with Crohn's disease and surgical outcomes.

## **Methods**

The authors conducted a thorough literature search till march 2021 in the PubMed dataset. We used the Medline subheadings and keywords "Vedolizumab", "Entyvio", "MLN0002", "MLN02", "MLN-0002", "MLN-02", "Crohn's Enteritis", "Regional Enteritis", "Crohn's Disease", "Crohns Disease", "Granulomatous Enteritis", "Ileocolitis", "Granulomatous Colitis", "Terminal Ileitis", "Regional Ileitis", "Perioperative", "complications", "Post-surgical" and "surgical".

## **Pathophysiology**

Vedolizumab is an anti-integrin biological agent. It prevents leukocyte integrin  $\alpha4\text{-}\beta7$  from combining with addressin MADCAM-1 that blocks its effect in the endothelial wall, leukocyte migration from the endothelial layer to the other intestinal layers [32]. It is gut selective, being the first of its kind. Vedolizumab got approved for the management and treatment of ulcerative colitis (UC) and CD with increasing its use globally [33]. The impairment of anastomotic healing by preoperative vedolizumab in CD surgery is still controversial.

## **Evidence of perioperative consequences of vedolizumab**

We investigated ten studies with different methodologies (mostly multicenter cohorts or retrospective single-center) and comparison groups. Definitive evidence is still unclear and controversial. The expected outcomes showed no statistical difference in most studies. However, due to nonuniformity between the groups analyzed in each study, these outcomes can not represent hard evidence for vedolizumab's impact on surgical results.

A posthoc analysis by Shen et al. 2019 [34] of safety from GEMINI 1 and 2 in addition to studies investigating long-term safety for patients undergoing bowel surgery or colectomy reported postoperative complications, in 58 surgeries of GEMINI 1 and GEMINI 2, for 5.9% of vedolizumab-receiving patients (3/51) and 14.3% of the placebo group (1/7). While in the study of long-term safety, 7% of patients (157/2,243) underwent bowel resection/surgery or colectomy; 11 of these 157 patients developed postoperative complications. Twenty-three days was the median time from the final preoperative dose of vedolizumab and surgery in GEMINI 1, in GEMINI 2 was 20 days, and 39 to 40 days

for the study for long-term safety. While in the post-marketing phase, postoperative complications appeared in 19 patients out of 46,978 patients receiving vedolizumab for years from the post-marketing Vedolizumab Global Safety Database.

Lightner et al. 2019 [35] investigated 712 CD cases in a retrospective observational cohort study. One hundred twenty-seven patients received vedolizumab, 272 received anti-TNF $\alpha$ , 38 received ustekinumab, and 275 did not take any biological agents; through the 12 weeks prior to the abdominal surgery. No statistical difference was concluded between the groups regarding infectious complication rates or intraabdominal septic complications incidence, which increased with adjuvant corticosteroid therapy to biologics and former abdominal resection. Additionally, Yamada et al. 2017 [36] showed different results comparing 64 subjects with previous vedolizumab with 129 cases on anti-TNF $\alpha$  and 250 on conventional therapy. The results did not demonstrate any statistical significance in postoperative complications rates between the vedolizumab group and the two patients set ( $p = 0.35$ ). The authors found that anemia and preoperative steroid administration were dominant factors in multivariate analysis for increasing the complications. A study conducted by Park et al. 2018 [37] showed the same results -no complication risk increased with previous vedolizumab, using a similar methodology. The authors investigated two groups; vedolizumab and anti-TNF $\alpha$  groups. At the same time, they concluded no variations amongst them in surgical site infections (SSI) (14.9% in vedolizumab and 12% in anti-TNF $\alpha$ ). However, considering these results, they found vedolizumab to be safe preoperatively. Meanwhile, the authors of Kotze et al. 2018 [38] investigated 34 vedolizumab-receiving IBD cases undergoing 36 nonintestinal surgeries matched with 36 control interventions. The study was cross-matched. The analyzed

outcomes demonstrated no differences between the vedolizumab group and the control group in postoperative complications. These results between the vedolizumab group and the control group include SSI (6% to 0%, the p was 0.15), infections (14% to 8%, the p was 0.45), readmissions (11% to 6%, the p was 0.37) and reoperations (6% to 3%, the p was 0.56).

Novello et al. 2019 [39] included 980 IBD patients for comparing morbidity rates after surgery following receiving vedolizumab versus other biological agents or non. One hundred forty-one patients received vedolizumab. 59% of cases underwent abdominal procedures, including diverting or end ostomy formation. The primary multivariate analysis showed that receiving vedolizumab was separately related to higher morbidity incident ( $p < 0.001$ ), but not to infectious morbidity ( $p = 0.30$ ). They conducted a case-matched assessment for 95 vedolizumab-receiving cases compared to 95 cases taking infliximab or adalimumab. It did not demonstrate any variation in the general morbidity ( $p = 0.32$ ), SSI ( $p = 0.12$ ), or infectious complications ( $p = 0.15$ ).

Novello et al. 2018 [40] conducted a matched-case analysis comparing the total postoperative complications in ustekinumab-receiving patients preoperatively with vedolizumab-receiving patients. The authors investigated 103 CD subjects; 30 cases took ustekinumab preoperatively, and 73 received vedolizumab. Using univariate analysis, vedolizumab-receiving patients showed a higher incidence of postoperative complications ( $p = 0.009$ ) and ileus incidence ( $p = 0.015$ ). the analysis showed no significant statistical difference in the main outcomes. Moreover, Lightner et al. 2018 [41] performed a cohort study of adult IBD cases, which was multicenter retrospective. A total of 435 patients had abdominal surgery; 146 patients took vedolizumab through 12

prior to the abdominal intervention, and 289 patients took anti-TNF $\alpha$  treatment.

Vedolizumab-receiving subjects had a higher risk of any postoperative SSI ( $P < 0.01$ ), deep space SSI (the  $P$  was 0.39), superficial SSI (the  $P$  was less than 0.01), and diverting mucocutaneous stoma separation (the  $P$  was less than 0.00) in comparison with cases on anti-TNF $\alpha$  agents. On multivariate assessment, after regulating body mass index, steroids at the time of surgery, and institution, receiving vedolizumab continued to be a considerable predictor for postoperative SSI ( $P < 0.01$ ). Lightner et al. 2017 [42] investigated 94 subjects from the Mayo Clinic with former vedolizumab use. They were divided into groups; the anti-TNF $\alpha$  therapy groups and the conventional treatment group, compared retrospectively for postoperative complications. Vedolizumab group had a higher incidence of SSI ( $p < 0.001$ ) and postoperative infections than the rest of the groups. These outcomes made vedolizumab perioperative safety use questionable.

However, the vedolizumab-receiving cases with refractory CD were severe with laparoscopic approaches and less initial anastomoses. Lightner et al. 2016 [43] performed a retrospective cohort for adult IBD cases who had abdominal surgeries. The study included 94 subjects taking vedolizumab 12 weeks prior to their surgery and subjects taking either anti-TNF $\alpha$  or no biologics as the control group. Fifty patients underwent postoperative complications representing 53%; 35 were SSIs representing 36%. The vedolizumab-receiving group showed higher rates of postoperative complications.

Nonspecific postoperative infections occurred 53% with vedolizumab versus 33% with anti-TNF $\alpha$  and 28% with no biologics use ( $P < 0.001$ ) while SSI occurred 37% versus 10% and 13% ( $P < 0.001$ ), respectively. And yet, vedolizumab exposure is related to a

significantly higher incidence of SSI postoperatively ( $P<0.001$ ) on multivariate and univariate evaluation.

Other systematic reviews with meta-analyses [33, 44, 45] were also conducted and no statistically significant difference in cases with preoperative vedolizumab use was observed concerning an increased incidence of postoperative complications. A summary of these studies is described in more detail in Table 1.

UNDER PEER REVIEW

ID	Disease	Number of patients treated	Design	Type of surgery	Main outcomes	Main finding
Shen 2019	CD, UC	GEMINI 1: UC, Vedolizumab (n=15), Placebo (n=3) GEMINI 2: CD Vedolizumab (n=36), Placebo (n=4) GEMINI LTS study: all vedolizumab-treated: UC (n=55), CD (n=102).	Post hoc analysis	Colectomy and bowel surgery/resection	Post-operative complications	In clinical trials, complications were infrequent with a slight difference. In the post-marketing phase, the frequency of complications was low.
Novello 2019	CD, UC	980; 141 vedolizumab	A case-matched analysis	Abdominal surgery for IBD	Postoperative morbidity of IBD surgery following treatment with vedolizumab.	Preoperative vedolizumab was not associated with an increased morbidity rate.
Lightner 2019	CD.	712; 272 anti-TNF, 127 vedolizumab, 38 ustekinumab, and 275 no biologic therapy	Retrospective Single-center	Major abdominal operation	Thirty-day overall postoperative infectious complications and intraabdominal septic complications.	The intended outcomes rate did not increase with preoperative biologics exposure. Increased rates were noted with corticosteroids adjuvant therapy or previous abdominal surgery.
Novello 2018	CD.	103; 30 ustekinumab, 73 vedolizumab	A case-matched analysis	Colorectal surgery	Short-term postoperative complication rate.	The analysis showed no significant statistical difference in the main outcomes.
kotze 2018	CD, UC	70; 34 vedolizumab, 36 control	A case-matched study	Non intestinal surgical procedure	overall risk of early postoperative infectious complications (up to 30 days after surgery), readmissions, reoperations, surgical site infections, and other infections.	Vedolizumab-receiving IBD patients showed no increased risk of complications over the matched controls.
Lightner 2018	CD, UC	435; 146 vedolizumab, 289 anti-TNF	Retrospective Multicenter Cohort	major abdominal or pelvic colorectal operation.	The rate of 30-day postoperative surgical site infection	Vedolizumab-receiving subjects had a higher risk for postoperative SSIs compared with anti-TNF $\alpha$ .
Yung 2018	CD, UC	1080; 281 vedolizumab, 364 anti-TNF, 435 no biologics	systematic review and meta-analysis	Abdominal surgery for IBD	Overall postoperative complications, infectious complications, surgical site infections, need for repeat surgery, and major postoperative complications	There was no increased risk of postoperative complications. The overall complications' risk may be lower in UC with vedolizumab.
Law 2018	CD, UC	1332; 307 vedolizumab, 490 anti-TNF, 535 no biologics	systematic review and meta-analysis	Abdominal surgery for IBD	Postoperative infectious complications and overall postoperative complications.	There was no increased risk of postoperative infections or other complications with vedolizumab.
Park 2018	CD, UC	186; 94 vedolizumab, 92 anti-TNF	Retrospective cohort	Abdominal surgery for IBD	The risk of surgical site infections	There was no increased risk of SSI with perioperative vedolizumab.
Yamada 2017	CD, UC	443; 64 vedolizumab, 129 anti-TNF, 250 no biologics	Retrospective cohort	Major abdominal operation	The rates of 30-day postoperative complications	There was no effect on the risk of 30-day postoperative complications with perioperative vedolizumab in UC and CD.
Lightner 2017	CD	312; 100 vedolizumab, 107 anti-TNF, 105 no biologics	Retrospective cohort	Major abdominal operation	The rates of 30-day postoperative complications	62% of CD patients receiving vedolizumab within 12 weeks before the abdominal operation experienced a significantly higher risk of 30-day postoperative SSI.
Engel 2017	CD, UC	1565; 571 UC, 994 CD	Systematic review	Major abdominal operation	Efficacy and safety data with vedolizumab in induction and maintenance treatment in adults with IBD.	Vedolizumab is effective in CD and UC. It has a good safety profile in the Real-world Experience.
Lightner 2016	CD, UC	392; 94 vedolizumab, 126 anti-TNF, 172 no biologics	Retrospective cohort	Major abdominal operation	The rates of 30-day postoperative complications	37% of IBD patients receiving vedolizumab within 12 weeks before an abdominal operation experienced a significantly higher risk of 30-day postoperative SSI.

IBD, inflammatory bowel diseases; LTS, long-term safety; UC, ulcerative colitis; CD, Crohn's disease; TNF, tumor necrosis factor; SSI, surgical site infections.

Table 1: Main characteristics and outcomes of studies assessed the influence of vedolizumab in postoperative complications.

## **Limitations**

The studies included have different methodologies (mostly multicenter cohorts or retrospective single-center), which may have information biases. Some records studied IBD patients, not CD alone, and nonuniformity existed in the comparisons made between the different groups' studies.

Additionally, many routing factors unquestionably affect CD's postoperative outcomes and complications in patients undergoing intestinal resection, like impaired nutritional condition [46], unsuitable abdominal settings, and steroids' previous use [47]. One of these or more might exist for patients indicated for surgery who are already on these biological agents. Therefore, in patients with malnutrition, with prior steroids, and/or anemia, the surgical strategy can be impacted. More significantly, when unsuitable abdominal settings are present in operation, such as bowel dilatation, abscesses, and intestinal incomplete or complete obstruction, the operational plan needs to be redefined.

The novel global surgical direction towards the creation of stomas rather than primary anastomoses has become the rule for cases with these conditions, not due to using the biological drugs per se, but for more critical patients with the higher risk of complications by definition.

## **Recommendations**

So far, a definitive conceptual proof explaining the postoperative effect of biological agents on the CD course has not been clearly shown. The cause-effect relationship that may be established by drug serum levels, as an example, was not evident in the most

critical prospective study till now. Moreover, records that could explain tissue diffusion of these drugs in the surgical specimens are also missing.

The database, including biological agents with different action mechanisms, is still in its initial years in international literature due to the relatively recent vedolizumab approval in the clinical practice. As presented in this review, in spite of the initial warning record [43] that demonstrated the possibility of complications increases with previously taking vedolizumab, most of the recently published studies showed opposite outcomes [36, 37]. More prospective trials are required to confirm the vedolizumab effect in the preoperative period.

Additionally, it is essential to state that a study conducted in Germany showed decreased systemic circulation classical monocytes (M2 macrophages) with inhibiting the integrin  $\alpha 4\text{-}\beta 7$ , caused by vedolizumab, which could impact wound healing [48]. Therefore, owing to this essential basic scientific concept, added to the fact that no prospective studies with vedolizumab were published to date, personalized, multidisciplinary evaluations and decisions should be made for each case independently in the clinical practice.

We recommend that prospective analysis and trials enroll a significant case sample with strict details and more comparison groups to design an appropriate study to generate more meaningful results to resolve the controversy and aim for more reliable and high-quality evidence.

## **Conclusion**

Using vedolizumab perioperatively seems safe; however, more prospective interventional studies are needed to clarify the effect of vedolizumab use in the preoperative period.

Although most of the mentioned studies showed no statistically significant increase in CD patients' postoperative outcomes, a definitive relationship from the accessible data is still contentious. Personalized, multidisciplinary evaluations and decisions should be made for each case independently, adjusting the surgical plan giving to the involved risk factors.

UNDER PEER REVIEW

## References

1. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV, Jr.: Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. *Clin Gastroenterol Hepatol*. 2017, 15:857-863. 10.1016/j.cgh.2016.10.039
2. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology*. 2007, 132:52-65. 10.1053/j.gastro.2006.11.041
3. Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG: Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. *Gastroenterology*. 2019, 157:1007-1018.e1007. 10.1053/j.gastro.2019.06.038
4. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet*. 2002, 359:1541-1549. 10.1016/s0140-6736(02)08512-4
5. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. *Gastroenterology*. 2006, 130:323-333; quiz 591. 10.1053/j.gastro.2005.11.030
6. Lowenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, van der Woude CJ, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D'Haens G: Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. *Gastroenterology*. 2019, 157:997-1006.e1006. 10.1053/j.gastro.2019.05.067
7. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. *Gastroenterology*. 2004, 126:402-413. 10.1053/j.gastro.2003.11.014
8. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S: Certolizumab pegol for the treatment of Crohn's disease. *N Engl J Med*. 2007, 357:228-238. 10.1056/NEJMoa067594
9. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF: Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. *Ann Intern Med*. 2007, 146:829-838. 10.7326/0003-4819-146-12-200706190-00159
10. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ: Maintenance therapy with certolizumab pegol for Crohn's disease. *N Engl J Med*. 2007, 357:239-250. 10.1056/NEJMoa062897
11. Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S: Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. *Clin Gastroenterol Hepatol*. 2016, 14:1385-1397.e1310. 10.1016/j.cgh.2016.04.039
12. Bernstein CN, Eliakim A, Fedail S, Fried M, Geary R, Goh KL, Hamid S, Khan AG, Khalif I, Ng SC, Ouyang Q, Rey JF, Sood A, Steinwurz F, Watermeyer G, LeMair A: World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. *J Clin Gastroenterol*. 2016, 50:803-818. 10.1097/mcg.0000000000000660

13. Brouquet A, Maggiori L, Zerbib P, Lefevre JH, Denost Q, Germain A, Cotte E, Beyer-Berjot L, Munoz-Bongrand N, Desfourneaux V, Rahili A, Duffas JP, Pautrat K, Denet C, Bridoux V, Meurette G, Faucheron JL, Loriau J, Guillon F, Vicaut E, Benoist S, Panis Y: Anti-TNF Therapy Is Associated With an Increased Risk of Postoperative Morbidity After Surgery for Ileocolonic Crohn Disease: Results of a Prospective Nationwide Cohort. *Ann Surg.* 2018, 267:221-228. 10.1097/sla.0000000000002017
14. de Buck van Overstraeten A, Eshuis EJ, Vermeire S, Van Assche G, Ferrante M, D'Haens GR, Ponsioen CY, Belmans A, Buskens CJ, Wolthuis AM, Bemelman WA, D'Hoore A: Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres. *Br J Surg.* 2017, 104:1713-1722. 10.1002/bjs.10595
15. Subramanian V, Saxena S, Kang JY, Pollok RC: Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. *Am J Gastroenterol.* 2008, 103:2373-2381. 10.1111/j.1572-0241.2008.01942.x
16. Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS: Clinical use of anti-TNF therapy and increased risk of infections. *Drug Healthc Patient Saf.* 2013, 5:79-99. 10.2147/dhps.s28801
17. Yang ZP, Hong L, Wu Q, Wu KC, Fan DM: Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis. *Int J Surg.* 2014, 12:224-230. 10.1016/j.ijsu.2013.12.015
18. Wong DJ, Roth EM, Feuerstein JD, Poylin VY: Surgery in the age of biologics. *Gastroenterol Rep (Oxf).* 2019, 7:77-90. 10.1093/gastro/goz004
19. Waterland P, Athanasiou T, Patel H: Post-operative abdominal complications in Crohn's disease in the biological era: Systematic review and meta-analysis. *World J Gastrointest Surg.* 2016, 8:274-283. 10.4240/wjgs.v8.i3.274
20. Narula N, Charleton D, Marshall JK: Meta-analysis: peri-operative anti-TNFalpha treatment and post-operative complications in patients with inflammatory bowel disease. *Aliment Pharmacol Ther.* 2013, 37:1057-1064. 10.1111/apt.12313
21. Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH: Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. *Inflamm Bowel Dis.* 2012, 18:2404-2413. 10.1002/ibd.22954
22. Holubar SD, Holder-Murray J, Flasar M, Lazarev M: Anti-Tumor Necrosis Factor-alpha Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFR Position Paper. *Inflamm Bowel Dis.* 2015, 21:2658-2672. 10.1097/mib.0000000000000603
23. El-Hussuna A, Theede K, Olaison G: Increased risk of post-operative complications in patients with Crohn's disease treated with anti-tumour necrosis factor alpha agents - a systematic review. *Dan Med J.* 2014, 61:A4975.
24. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE: ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* 2018, 113:481-517. 10.1038/ajg.2018.27
25. Duijvestein M, Battat R, Vande Casteele N, D'Haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG: Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. *Curr Treat Options Gastroenterol.* 2018, 16:129-146. 10.1007/s11938-018-0175-1
26. Danese S, Roda G, Peyrin-Biroulet L: Evolving therapeutic goals in ulcerative colitis: towards disease clearance. *Nat Rev Gastroenterol Hepatol.* 2020, 17:1-2. 10.1038/s41575-019-0211-1
27. Olivera P, Spinelli A, Gower-Rousseau C, Danese S, Peyrin-Biroulet L: Surgical rates in the era of biological therapy: up, down or unchanged? *Curr Opin Gastroenterol.* 2017, 33:246-253. 10.1097/mog.0000000000000361

28. Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G, de Buck van Overstraeten A, Burke JP, Buskens CJ, Colombo F, Dias JA, Eliakim R, Elosua T, Gecim IE, Kolacek S, Kierkus J, Kolho KL, Lefevre JH, Millan M, Panis Y, Pinkney T, Russell RK, Shwaartz C, Vaizey C, Yassin N, D'Hoore A: ECCO-ESCP Consensus on Surgery for Crohn's Disease. *J Crohns Colitis*. 2018, 12:1-16. 10.1093/ecco-jcc/jjx061
29. Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V: Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. *Inflamm Bowel Dis*. 2015, 21:2879-2885. 10.1097/mib.0000000000000561
30. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A: Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2013, 369:699-710. 10.1056/NEJMoa1215734
31. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV, Jr., Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG: The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut*. 2017, 66:839-851. 10.1136/gutjnl-2015-311079
32. Kotze PG, Ma C, Almutairdi A, Al-Darmaki A, Devlin SM, Kaplan GG, Seow CH, Novak KL, Lu C, Ferraz JGP, Stewart MJ, Buresi M, Jijon H, Mathivanan M, Heatherington J, Martin ML, Panaccione R: Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. *Aliment Pharmacol Ther*. 2018, 48:626-637. 10.1111/apt.14919
33. Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U: Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. *J Crohns Colitis*. 2018, 12:245-257. 10.1093/ecco-jcc/jjx143
34. Shen B, Blake A, Lasch K, Smyth M, Bhayat F: Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience. *Gastroenterol Rep (Oxf)*. 2019, 7:322-330. 10.1093/gastro/goz034
35. Lightner AL, McKenna NP, Alsughayer A, Harmsen WS, Taparra K, Parker ME, Raffals LE, Loftus EV, Jr.: Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles? *Dis Colon Rectum*. 2019, 62:1352-1362. 10.1097/dcr.0000000000001482
36. Yamada A, Komaki Y, Patel N, Komaki F, Aelvoet AS, Tran AL, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A: Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. *Am J Gastroenterol*. 2017, 112:1423-1429. 10.1038/ajg.2017.201
37. Park KT, Sceats L, Dehghan M, Trickey AW, Wren A, Wong JJ, Bensen R, Limketkai BN, Keyashian K, Kin C: Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. *Aliment Pharmacol Ther*. 2018, 48:340-346. 10.1111/apt.14842
38. Kotze PG, Ma C, McKenna N, Almutairdi A, Kaplan GG, Raffals LE, Loftus EV, Jr., Panaccione R, Lightner AL: Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. *Therap Adv Gastroenterol*. 2018, 11:1756284818783614. 10.1177/1756284818783614
39. Novello M, Stocchi L, Steele SR, Holubar SD, Duraes LC, Kessler H, Shawki S, Hull LT: Case-matched Comparison of Postoperative Outcomes Following Surgery for Inflammatory Bowel Disease After Exposure to Vedolizumab vs Other Biologics. *J Crohns Colitis*. 2020, 14:185-191. 10.1093/ecco-jcc/jjz129

40. Novello M, Stocchi L, Holubar S, Shawki S, Lipman J, Gorgun E, Hull T, Steele SR: Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis. *Int J Colorectal Dis.* 2019, 34:451-457. 10.1007/s00384-018-3212-6
41. Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochhar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV, Jr.: Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. *Inflamm Bowel Dis.* 2018, 24:871-876. 10.1093/ibd/izx076
42. Lightner AL, McKenna NP, Tse CS, Raffals LE, Loftus EV, Jr., Mathis KL: Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. *Aliment Pharmacol Ther.* 2018, 47:573-580. 10.1111/apt.14459
43. Lightner AL, Raffals LE, Mathis KL, Cima RR, Tse CS, Pemberton JH, Dozois EJ, Loftus EV: Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease. *J Crohns Colitis.* 2017, 11:185-190. 10.1093/ecco-jcc/jjw147
44. Yung DE, Horesh N, Lightner AL, Ben-Horin S, Eliakim R, Koulaouzidis A, Kopylov U: Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2018, 24:2327-2338. 10.1093/ibd/izy156
45. Law CCY, Narula A, Lightner AL, McKenna NP, Colombel JF, Narula N: Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease. *J Crohns Colitis.* 2018, 12:538-545. 10.1093/ecco-jcc/jjy022
46. Yamamoto T, Shimoyama T, Umegae S, Kotze PG: Impact of Preoperative Nutritional Status on the Incidence Rate of Surgical Complications in Patients With Inflammatory Bowel Disease With Vs Without Preoperative Biologic Therapy: A Case-Control Study. *Clin Transl Gastroenterol.* 2019, 10:e00050. 10.14309/ctg.0000000000000050
47. Kotze PG, Saab MP, Saab B, da Silva Kotze LM, Olandoski M, Pinheiro LV, Martinez CA, Ayrizono ML, Magro DO, Coy CS: Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease. *Dig Dis Sci.* 2017, 62:456-464. 10.1007/s10620-016-4400-2
48. Schleier L, Wiendl M, Heidbreder K, Binder MT, Atreya R, Rath T, Becker E, Schulz-Kuhnt A, Stahl A, Schulze LL, Ullrich K, Merz SF, Bornemann L, Gunzer M, Watson AJM, Neufert C, Atreya I, Neurath MF, Zundler S: Non-classical monocyte homing to the gut via  $\alpha 4\beta 7$  integrin mediates macrophage-dependent intestinal wound healing. *Gut.* 2020, 69:252-263. 10.1136/gutjnl-2018-316772